Literature DB >> 9457036

Current options in prosthetic vascular graft infection.

P K Henke1, T M Bergamini, S M Rose, J D Richardson.   

Abstract

Debate continues over which procedure is the best treatment for prosthetic graft infections. We retrospectively reviewed the medical records at our institution for all vascular graft infections that occurred from 1985 to 1995 to evaluate their occurrence, treatment, and outcome. Twenty-four patients had prosthetic graft infections. The average patient age was 62 years, and 67 per cent of the patients studied were men. The initial operation was for treatment of occlusive disease in 92 per cent of the patients, and aortofemoral bypasses were the most common procedures performed (15 of 24 patients, 63%). The average interval from graft implantation to presentation of infection was 29 months. In lower-extremity bypasses, the site of infection was most commonly in the groin (87%). Gram-positive organisms, including coagulase-negative Staphylococcus (32%) and Staphylococcus aureus (28%), were the most frequently isolated bacteria. Thirty procedures were performed for management of the graft infections. Extra-anatomic bypass was associated with no recurrent graft infections. Graft preservation was successful in two cases of early S. aureus infection (less than 1 year after original procedure), and in situ graft replacement was successful in all four cases of late-appearing coagulase-negative Staphylococcus infection (more than 1 year after original procedure). Both treatments failed in all five cases of Gram-negative infection (P = 0.008 by Fisher's exact test). The overall mortality and amputation rates were 17 per cent and 21 per cent, respectively, without significant differences between the treatment modalities. Extra-anatomic bypass remains the best treatment for prosthetic graft infection. In situ replacement and graft preservation treatments should be selective and based on presentation of the infection and the type of pathogenic organism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457036

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  8 in total

1.  Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2.

Authors:  Paulus H S Kwakman; Anje A te Velde; Christina M J E Vandenbroucke-Grauls; Sander J H van Deventer; Sebastian A J Zaat
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

2.  Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Giuseppina D'Amato; Wojciech Kamysz; Federico Mocchegiani; Valerio Sisti; Carmela Silvestri; Jerzy Łukasiak; Marco Rocchi; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Prosthetic graft infections involving the femoral artery.

Authors:  Jeffrey J Siracuse; Prathima Nandivada; Kristina A Giles; Allen D Hamdan; Mark C Wyers; Elliot L Chaikof; Frank B Pomposelli; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2013-01-09       Impact factor: 4.268

4.  Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Federico Mocchegiani; Alessandra Riva; Maria Simona Del Prete; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

5.  A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci.

Authors:  Naomi Balaban; Yael Gov; Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Federico Mocchegiani; Fiorenza Orlando; Giuseppina D'Amato; Vittorio Saba; Giorgio Scalise; Sabina Bernes; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

6.  Biological behaviour of an endothelial cell line (HPMEC) on vascular prostheses grafted with hydroxypropylgamma-cyclodextrine (HPgamma-CD) and hydroxypropylbeta-cyclodextrine (HPbeta-CD).

Authors:  N Blanchemain; F Chai; S Haulon; V Krump-Konvalinkova; M Traisnel; M Morcellet; B Martel; C J Kirkpatrick; H F Hildebrand
Journal:  J Mater Sci Mater Med       Date:  2008-02-12       Impact factor: 3.896

7.  Prosthetic vascular graft infection: a multi-center review of surgical management.

Authors:  Eleonore Zetrenne; Bryan C McIntosh; Mark H McRae; Richard Gusberg; Gregory R D Evans; Deepak Narayan
Journal:  Yale J Biol Med       Date:  2007-09

8.  The efficacy of the quorum sensing inhibitor FS8 and tigecycline in preventing prosthesis biofilm in an animal model of staphylococcal infection.

Authors:  Oriana Simonetti; Oscar Cirioni; Federico Mocchegiani; Ivana Cacciatore; Carmela Silvestri; Leonardo Baldassarre; Fiorenza Orlando; Pamela Castelli; Mauro Provinciali; Marco Vivarelli; Erika Fornasari; Andrea Giacometti; Annamaria Offidani
Journal:  Int J Mol Sci       Date:  2013-08-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.